

## A Concise Diastereoselective Synthesis of the Natural (2*R*, 3*S*)-2-Hydroxymethyl-3-Hydroxy Pyrrolidine


Dominique Griffart-Brunet and Nicole Langlois\*

Institut de Chimie des Substances Naturelles, C.N.R.S., 91190 Gif-sur-Yvette, France

*Key Words* : pyroglutamic acid, hydroxylated pyrrolidine, epoxidation, epoxide opening, *Castanospermum*.


**Abstract.** (2*R*, 3*S*)-2-hydroxymethyl-3-hydroxy pyrrolidine **4**, a constituent of *Castanospermum australe*,<sup>1</sup> was synthesized from (*S*)-pyroglutamic acid through diastereoselective epoxidation of  $\alpha$ ,  $\beta$ -unsaturated pyrrolidone **8**.

Optically active polyhydroxylated pyrrolidines have recently received considerable attention due to their role as intermediates for the synthesis of more complex bioactive molecules or to their own biological activities.<sup>2</sup> Some of them, as DBA1 **1** (D-1,4-dideoxy-1,4-iminoarabinitol), are selective glycosidase inhibitors<sup>3</sup> whereas the enantiomer LBA1 exhibit anti-HIV properties.<sup>4</sup>



Both enantiomers of pyroglutamic acid **2** have already proven to be useful in the syntheses of many substituted pyrrolidines with defined configurations. In continuation of our work starting from **2** as a chiral source in synthesis<sup>5</sup>, we postulated that several interesting hydroxylated pyrrolidines could be easily accessible from (*S*) (or *R*) pyroglutaminol **3**.<sup>6</sup> For this purpose, we planned to prepare conveniently protected 3, 4-epoxy derivatives. These oxiranes could constitute versatile intermediates, depending on the nucleophile used to open the epoxide ring. This approach is illustrated here by the synthesis of the natural (2*R*, 3*S*)-2-hydroxymethyl-3-hydroxy pyrrolidine **4**,<sup>7</sup> isolated from *Castanospermum australe*.<sup>1</sup>

The known pyrrolidones **5**<sup>8</sup> and **6**<sup>9</sup> were deprotonated respectively by LiHMDS and LDA (1 equiv, 78°) to introduce the conjugated double bond by classical phenylselenation (PhSeCl), followed by selenoxide elimination. In both cases hydrogen peroxide was used as an oxidant of the phenylselenides, leading respectively to **7**<sup>10</sup> and to the previously described compound **8**.<sup>11</sup>



The epoxidation of these  $\alpha$ ,  $\beta$ -unsaturated pyrrolidones proved to be more difficult than anticipated, which is also supported by recent results.<sup>12</sup> Several methods of electron deficient alkene epoxidation were investigated :

Dimethyldioxirane is known to epoxidize the double bond of  $\alpha$ ,  $\beta$ -unsaturated ketones, acids and esters.<sup>13</sup> This method was applied to the compound **7**, the *N*-methoxycarbonyl substitution of which provided some ketonic character to the conjugated  $\gamma$ -lactam carbonyl, but it was ineffective, and gave rise to only *O*-deprotected pyrrolidone **10**. The compound **8** lacked reactivity towards hydrogen peroxide in presence of sodium bicarbonate.<sup>14</sup> The use of sodium perborate<sup>15</sup> led to **9a** in poor yield (11%), but all attempts to improve yield by increasing the reaction time failed.

Better results were obtained with conjugate addition of lithium *tert*-butylhydroperoxide<sup>16,17</sup>, which led to the epoxides **9** in 46% isolated yield. The ratio of diastereomers **9a** and **9b** (**9a** : **9b** = 87 : 13) was determined by <sup>1</sup>H NMR in C<sub>6</sub>D<sub>6</sub>, the chemical shift of the amino acetal proton was rather different in **9a** (6.46ppm)<sup>18</sup> and **9b** (6.04 ppm).<sup>19</sup> These diastereoisomers were separated chromatographically. The nitrogen and the hydroxymethyl groups of the major epoxide **9a** were deprotected by acidic hydrolysis without opening of the epoxide ring (CF<sub>3</sub>CO<sub>2</sub>H, THF-H<sub>2</sub>O), leading to primary alcohol **11a**, which was characterized through its

acetate **12a** (57% isolated yield from **9a**).<sup>20</sup> In the same conditions, the isomer **9b** gave rise to **12b**. Thus **9a** and **9b** differ by relative configuration of the epoxide ring. The diastereoselectivity was interpreted as a consequence of the steric hindrance due to the oxazolidine methylene of the constrained compound **8** and the configurations were confirmed by X ray analysis of **9a**<sup>21</sup>, but the stereocontrol was not so efficient<sup>22</sup> as observed in the conjugate addition of dialkylthiocuprates.<sup>23</sup>

It is noteworthy that no epoxide could be isolated in the same conditions starting from the unsaturated pyrrolidinone **7** which was recovered along with several degradation products.<sup>24</sup>

LiAlH<sub>4</sub> reduction of **12a** gave rise to (2*R*, 3*S*)-2-hydroxymethyl-3-hydroxy pyrrolidine **4** in 80% yield. Its hydrochloride was spectroscopically identical with the natural product isolated from *Castanospermum australe*;<sup>1,25</sup> (2*S*,4*R*)-4-hydroxy prolinol hydrochloride **13**, prepared by deprotection<sup>26</sup> of its N-BOC derivative<sup>27</sup>, was not detected in the NMR spectra of the reduction product of **12a**, indicating a high stereoselectivity of the opening of epoxide ring by the hydride ion.

The use of optically pure 3, 4-epoxy pyrrolidone **9a** in further syntheses are under current investigation in our laboratory.

**Acknowledgments :** We thank Professor J. M. Williams, University College of Swansea, U. K., for mass and NMR spectra of natural (2*R*, 3*S*)-2-hydroxymethyl-3-hydroxy pyrrolidine and the CNRS for a grant (D. G.).

## References and Notes

- Nash, R. J.; Bell, E. A.; Fleet, G.W.J.; Jones, R. H.; Williams J.M. J. *Chem. Soc. Chem. Comm.* **1985**, 738-740. For clarity, the same numbering of the pyrrolidine ring was used for all derivatives leading to pyrrolidine **4**.
- Fleet, G.W.J.; Witty, D. R. *Tetrahedron Asymmetry* **1990**, *1*, 119-136.
- Robinson, K. M.; Rhinehart B. L.; Ducep, J. B.; Danzin, C. *Drugs of the Future* **1992**, *17*, 705-720.
- Karpas, A.; Fleet, G.W.J.; Dwek, R. A.; Petursson, S.; Namgoong S. K.; Ramsden, N. G.; Jacob, B. S.; Rademacher, T. W. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 9229-9233.
- Langlois, N.; Rojas, A. *Tetrahedron* **1993**, *49*, 77-80 and references therein. (S)-Pyroglutamic acid was kindly provided by UCIB (Usines Chimiques d'Ivry-la-Bataille).
- Saijo, S.; Wada, M.; Himizu, J.; Ishida, A. *Chem. Pharm. Bull.* **1980**, *28*, 1449-1458.
- a) Ikota, N.; Hanaki, A. *Heterocycles* **1988**, *27*, 2535-2537. b) Hirai, Y.; Chintani, M.; Yamazaki, T.; Momose, T. *Chem. Lett.* **1989**, 1449-1452.
- Langlois, N.; Andriamialisoa, R. Z. *Tetrahedron Letters* **1988**, *29*, 3259-3262.
- a) Thottathil, J. K.; Moniot, J. L.; Mueller, R. H.; Wong, M. K. Y.; Kissick, T. P. *J. Org. Chem.* **1986**, *51*, 3140-3143. b) Thottathil, J. K.; Przybyla, C.; Malley, M.; Gougoutas, J. Z. *Tetrahedron Letters* **1986**, *27*, 1533-1536.
- 7** :  $[\alpha]_D^{20} = -197$  (c = 0.8, CHCl<sub>3</sub>) ; IR : 2987, 1792, 1736, cm<sup>-1</sup>; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>, δ = 0, TMS, J = Hz) : 7.33 (m, 1H, C-3-H), 6.16 (dd, 1H, J<sub>3,4</sub> = 6 and J = 1, C-4-H), 4.77 (m, 1H, C-2-H), 4.68 (m, 1H,

- OCHO), 4.06 and 3.68 (2m, 2H, OCH<sub>2</sub>), 3.91 (s, 3H, CO<sub>2</sub>CH<sub>3</sub>), 3.58 and 3.46 (2m, 2H, CH<sub>2</sub>), 1.29 (2d, 3H, J ~ 5.5, CHCH<sub>3</sub>), 1.19 (t, 3H, J = 7, CH<sub>2</sub>CH<sub>3</sub>).; MS (m/z) : 228 (M<sup>+</sup>- CH<sub>3</sub>), 213, 198, 154 (100%), 141, 109, 73 ; HRMS calcd for C<sub>10</sub>H<sub>14</sub>NO<sub>5</sub> : 228.0872, obsd : 228.0900.
11. Hamada, Y.; Hara, O.; Kawai, A.; Kohno, Y.; Shioiri, T. *Tetrahedron* **1991**, *47*, 8635-8652.
  12. Woo, K. C.; Jones, K. *Tetrahedron Letters* **1991**, *32*, 6949-6952.
  13. Adam, W.; Hadjiarapoglou, L.; Nestler, B. *Tetrahedron Letters* **1990**, *31*, 331-334.
  14. Danishefsky, S.; Zamboni, R.; Kahn, M.; Etheredge, S. J. *J. Am. Chem. Soc.* **1981**, *103*, 3460-3467.
  15. Reed, K. L.; Gupton, J. T.; Solarz, T. L. *Synthetic Comm.* **1989**, *19*, 3579-3587.
  16. Meth-Cohn, O.; Moore, C.; Taljaard H. C. *J. Chem. Soc. Perkin Trans I* **1988**, 2663-2674.
  17. Lanier, M.; Haddach, M.; Pastor, R.; Riess, J. G. *Tetrahedron Letters* **1993**, *34*, 2469-2472.
  18. **9a** : mp : 90-2° C; [ $\alpha$ ]<sub>D</sub><sup>30</sup> = +237 (c = 0.9, CHCl<sub>3</sub>) ; IR : 1729, 850 ; <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>) : 7.38 and 7.06 (2m, aromatic H), 6.45 (s, 1H, OCHN), 3.46 (dd, 1H, J<sub>2,6a</sub> = 7, J<sub>2,6b</sub> = 9, C-2-H), 3.27 (dd, 1H, J<sub>6a,6b</sub> ~ 8, J<sub>2,6a</sub> = 7, C-6-Ha), 3.18 and 2.73 (2d, 2H, J<sub>3,4</sub> = 2.5, C-3-H and C-4-H), 2.63 (dd, 1H, J<sub>6a,6b</sub> ~ 8, J<sub>2,6b</sub> = 9, C-6-Hb) ; <sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>) : 175.44 (CO), 139.94 (C\*), 129.28 (CH), 129.22 (CH), 126.85 (CH), 88.92 (OCHN), 66.02 (CH<sub>2</sub>O), 60.09 (C-2-H), 57.27 and 53.63 (C-3 and C-4) ; MS (m/z) : 217 (M<sup>+</sup>-weak), 216, 147, 105 (100%) ; HRMS : calcd for C<sub>12</sub>H<sub>11</sub>NO<sub>3</sub> : 217.0739, obsd : 217.0730.
  19. **9b** : mp : 140-2° C (ether) ; [ $\alpha$ ]<sub>D</sub><sup>30</sup> = +181 (c = 0.4, CHCl<sub>3</sub>) ; IR : 1722, 870 ; <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>) : 7.49 and 7.1 (2m, aromatic H), 6.04 (s, 1H, OCHN), 3.50 (dd, 1H, J<sub>6a,6b</sub> ~ J<sub>2,6a</sub> ~ 8, , C-6-Ha), 3.44 (dd, 1H, J<sub>6a,6b</sub> ~ 8, J<sub>2,6b</sub> ~ 7, C-6-Hb), 3.06 (d, 1H, J<sub>3,4</sub> = 2.5) and 2.53 (dd, 1H, J = 2.5, J' ~ 2) : C-3-H and C-4-H, 3.02 (m, 1H, C-2-H).<sup>13</sup>C NMR (75 MHz, C<sub>6</sub>D<sub>6</sub>) : 171.5 (CO), 138.2(C\*), 128.8 (CH), 128.5 (CH), 126.0 (CH), 86.9 (OCHN), 65.5 (CH<sub>2</sub>O), 58.9 (CH), 57.1 (CH), 49.7 (CH) ; MS (m/z) : 217 (M<sup>+</sup>-weak), 216, 147, 105 (100%) ; Analyse : C<sub>12</sub>H<sub>11</sub>NO<sub>3</sub> , calcd% : C = 66.35, H = 5.10, N = 6.45 , found : C = 66.45, H = 5.32, N = 6.32.
  20. **12a** : mp : 66° C ; [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +26 (c = 0.8, CHCl<sub>3</sub>) ; IR : 3437, 1725, 848 ; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) : 5.91 (bs, 1H, NH), 4.19 (dd, 1H, J<sub>6a,6b</sub> = 11.5, J<sub>2,6a</sub> ~ 5.4, C-6-Ha), 4.13 (dd, 1H, J<sub>6a,6b</sub> = 11.5, J<sub>2,6b</sub> ~ 5, C-6-Hb), 4.03 (m, 1H, C-2-H), 3.92 (m, 1H) and 3.63, (m, 1H) : C-3-H and C-4-H, 2.12 (s, 3H, COCH<sub>3</sub>) ; MS (m/z) : 171 (M<sup>+</sup>), 111 (100%), 98 ; HRMS : (M<sup>+</sup>) calcd for C<sub>7</sub>H<sub>9</sub>NO<sub>4</sub> : 171.0531, obsd: 171.0529.
  21. Riche, C.; Chiaroni, A. to be published.
  22. The stereoselectivity was improved starting from the  $\alpha$ ,  $\beta$ -unsaturated bicyclic lactam protected with pivalaldehyde, but the chemical yields are lower.
  23. Hanessian, S.; Ratovelomanana, V. *Synlett* **1990**, 501-503.
  24. An attack of the carbonyl group by lithium *tert*-butylhydroperoxide could explain these results.
  25. **4** (hydrochloride) : [ $\alpha$ ]<sub>D</sub><sup>20</sup> = + 43.5 (c = 0.3, H<sub>2</sub>O), lit : [ $\alpha$ ]<sub>D</sub><sup>21</sup> = + 46.5 (c = 1, H<sub>2</sub>O)<sup>1</sup>, [ $\alpha$ ]<sub>D</sub><sup>23</sup> = + 43.8 (c = 1, H<sub>2</sub>O)<sup>7a</sup> ; comparison of <sup>1</sup>H NMR (300 MHz), <sup>13</sup>C NMR (75 MHz, D<sub>2</sub>O), and CIMS data.<sup>1</sup>
  26. Stahl, G. L.; Walter, R.; Smith, C. W. *J. Org. Chem.* **1978**, *43*, 2285-2286.
  27. Baker, G.L.; Fritschel, S.J.; Stille, J. R.; Stille J. K. *J. Org. Chem.* **1981**, *46*, 2954-2960.

(Received in France 15 October 1993; accepted 5 November 1993)